Shacham Shmueli, Einat
Geva, Ravit
Yarom, Nirit
Hubert, Ayala
Keynan, Rita
Kedem, Tal H.
Eini, Meir
Tamarkin, Dov
Shirvan, Mitchell
Funding for this research was provided by:
Foamix Pharmaceuticals (NA)
Article History
Received: 4 April 2018
Accepted: 10 December 2018
First Online: 4 January 2019
Compliance with ethical standards
:
: This study was supported by Foamix Pharmaceuticals. Einat Shacham Shmueli served as principal investigator on this study and has received a grant from Foamix Pharmaceuticals. Ravit Geva, Nirit Yarom, and Ayala Hubert served as investigators on this study. Rita Keynan, Tal Hetzroni Kedem, Dov Tarmakin, and Mitchell Shirvan are employees of Foamix Pharmaceuticals. Meir Eini serves as a consultant for Foamix Pharmaceuticals. Mitchell Shirvan, Tal Hetzroni, and Meir Eini receive stock options from Foamix Pharmaceuticals. Ravit Geva reports other from MSD, Novartis, BMS, Roche, Janssen, Takeda, Medison, Merck, and Pfizer, outside the submitted work. The authors state that they have full control of all primary data, and they agree to allow the journal to review their data if requested.